571 related articles for article (PubMed ID: 24751562)
21. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease.
Lafeber M; Spiering W; van der Graaf Y; Nathoe H; Bots ML; Grobbee DE; Visseren FL
Am Heart J; 2013 Aug; 166(2):282-289.e1. PubMed ID: 23895811
[TBL] [Abstract][Full Text] [Related]
22. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
[TBL] [Abstract][Full Text] [Related]
23. The Polypill in the prevention of cardiovascular disease.
Wald DS; Wald NJ
Prev Med; 2011 Jan; 52(1):16-7. PubMed ID: 21130112
[No Abstract] [Full Text] [Related]
24. [The polypill as cardiovascular prophylactic: clinical trials].
Sandli OK; Spigset O; Slørdal L
Tidsskr Nor Laegeforen; 2014 Mar; 134(6):620-3. PubMed ID: 24670510
[TBL] [Abstract][Full Text] [Related]
25. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
Roy A; Naik N; Srinath Reddy K
Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
[TBL] [Abstract][Full Text] [Related]
26. The polypill to prevent cardiovascular disease: physicians' perspectives.
Viera AJ
Curr Opin Cardiol; 2011 Sep; 26(5):438-42. PubMed ID: 21730826
[TBL] [Abstract][Full Text] [Related]
27. Polypill: Can its Potential Enhancement of Efficacy Trigger New Interest?
Chao J; Bansilal S
Glob Heart; 2016 Dec; 11(4):469-472. PubMed ID: 27938845
[No Abstract] [Full Text] [Related]
28. The feasibility of polypill for cardiovascular disease prevention in Asian Population.
Sukonthasarn A; Chia YC; Wang JG; Nailes J; Buranakitjaroen P; Van Minh H; Verma N; Hoshide S; Shin J; Turana Y; Tay JC; Teo BW; Siddique S; Sison J; Zhang YQ; Wang TD; Chen CH; Kario K
J Clin Hypertens (Greenwich); 2021 Mar; 23(3):545-555. PubMed ID: 33086429
[TBL] [Abstract][Full Text] [Related]
29. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.
Bramlage P; Sims H; Minguet J; Ferrero C
Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Roshandel G; Khoshnia M; Poustchi H; Hemming K; Kamangar F; Gharavi A; Ostovaneh MR; Nateghi A; Majed M; Navabakhsh B; Merat S; Pourshams A; Nalini M; Malekzadeh F; Sadeghi M; Mohammadifard N; Sarrafzadegan N; Naemi-Tabiei M; Fazel A; Brennan P; Etemadi A; Boffetta P; Thomas N; Marshall T; Cheng KK; Malekzadeh R
Lancet; 2019 Aug; 394(10199):672-683. PubMed ID: 31448738
[TBL] [Abstract][Full Text] [Related]
31. A polypill strategy to improve adherence: results from the FOCUS project.
Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
[TBL] [Abstract][Full Text] [Related]
32. Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
Ostovaneh MR; Poustchi H; Hemming K; Marjani H; Pourshams A; Nateghi A; Majed M; Navabakhsh B; Khoshnia M; Jaafari E; Mohammadifard N; Malekzadeh F; Merat S; Sadeghi M; Naemi M; Etemadi A; Thomas GN; Sarrafzadegan N; Cheng KK; Marshall T; Malekzadeh R
Eur J Prev Cardiol; 2015 Dec; 22(12):1609-17. PubMed ID: 25230980
[TBL] [Abstract][Full Text] [Related]
33. [Prevention of cardiovascular diseases using a combined pharmacological approach: is there any place for a "polypill"?].
Scheen AJ; Lefèbvre PJ; Kulbertus H
Rev Med Liege; 2003 Sep; 58(9):527-33. PubMed ID: 14626644
[TBL] [Abstract][Full Text] [Related]
34. Polypill treatments for cardiovascular diseases.
Webster R; Rodgers A
Expert Opin Drug Deliv; 2016; 13(1):1-6. PubMed ID: 26558898
[TBL] [Abstract][Full Text] [Related]
35. Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: the SPACE Collaboration.
Webster R; Patel A; Billot L; Cass A; Burch C; Neal B; Usherwood T; Thom S; Poulter N; Stanton A; Bots ML; Grobbee DE; Prabhakaran D; Reddy KS; Field J; Bullen C; Elley CR; Selak V; Rafter N; Wadham A; Berwanger O; Rodgers A;
Int J Cardiol; 2013 Dec; 170(1):30-5. PubMed ID: 24144927
[TBL] [Abstract][Full Text] [Related]
36. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
[TBL] [Abstract][Full Text] [Related]
37. Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.
López-Jaramillo P; González-Gómez S; Zarate-Bernal D; Serrano A; Atuesta L; Clausen C; Castro-Valencia C; Camacho-Lopez P; Otero J
Ther Adv Cardiovasc Dis; 2018 Jun; 12(6):169-174. PubMed ID: 29546816
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries.
Webster R; Patel A; Selak V; Billot L; Bots ML; Brown A; Bullen C; Cass A; Crengle S; Raina Elley C; Grobbee DE; Neal B; Peiris D; Poulter N; Prabhakaran D; Rafter N; Stanton A; Stepien S; Thom S; Usherwood T; Wadham A; Rodgers A;
Int J Cardiol; 2016 Feb; 205():147-156. PubMed ID: 26736090
[TBL] [Abstract][Full Text] [Related]
39. The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives.
Sanz G; Fuster V; Guzmán L; Guglietta A; Arnáiz JA; Martínez F; Sarria A; Roncaglioni MC; Taubert K
Am Heart J; 2011 Nov; 162(5):811-817.e1. PubMed ID: 22093195
[TBL] [Abstract][Full Text] [Related]
40. Requirement of pharmacological treatment for primary prevention of cardiovascular disease in asymptomatic office-executives in north-India.
Kasliwal RR; Bansal M; Mehrotra R; Agrawal V; Shrivastava S
Indian Heart J; 2010; 62(4):324-9. PubMed ID: 21280473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]